Back

State of the art in drug eluting stent technology.

27 August 2016 (13:30 - 13:48)
Organised by:
Congress Presentation Part of: Drug - Eluting stent PCI / stents: devices and technique ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Robert Byrne

Mater Private Hospital, Dublin (Ireland)

4 More presentations in this session

Presentation thumbnail
Ten year clinical outcome of a large registry with unrestricted use of DES
Professor R. van Geuns (Nijmegen, NL)
Abstract Slides Video
Presentation thumbnail
Long-term risk of stent thrombosis and restenosis after treatment with drug-eluting stents: A report from SCAAR
Professor E. Omerovic (Gothenburg, SE)
Abstract
Presentation thumbnail
Long-term clinical outcomes of biolimus-eluting stents with biodegradable versus bare-metal stents in patients with acute STEMI: 5 Year results of the randomized COMFORTABLE AMI trial.
Doctor L. Raber (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Future direction for research in drug - eluting stent technology.
Doctor M. Morice (Massy, FR)
Slides Video

Access the full session

Session thumbnail
Drug - Eluting stent

The Event

Event poster

ESC Congress 2016

27 August 2016 13:30 CET
You may be interested in
thumbnail
Congress Presentation
A baculoviral gene and drug-eluting (GDES) stent to promote re-endothelialization and prevent restenosis caused by atherosclerosis.
30 August 2024
thumbnail
Congress Presentation
Comparison of two iterations of the zotarolimus-eluting stents: an analysis of all-comer patients from two consecutive randomised clinical trials
28 August 2020
thumbnail
Webinar
Percutaneous interventions in patients with coronary artery disease and specific clinical conditions - IC Core Curriculum 6
9 November 2022
thumbnail
Congress Presentation
Drug-eluting balloon catheters in the treatment of left main coronary artery bifurcation lesions: 4-years follow-up
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources